Abstract
Cancer is a multifactorial disease including interactions of complex genetic and environmental factors. Clinical efficacy of anticancer chemotherapies is hampered by various factors including multidrug resistance (MDR). There is a strong need to discover more potent novel cancer drugs to kill cancer cells selectively. The recent new strategy for cancer treatment involves the design and synthesis of hybrid compounds as multitargeted anticancer agents. In this review, we focus on studies using hybrid compounds which were designed and synthesized from two or more different bioactive moieties conjugating them into a single hybrid drug. Hybrid compounds having more than a single target have been considered as more efficient and potent anticancer agents, since it is almost impossible to destroy cancer cells with a single target. Hybrid compounds overcome many disadvantages of single cancer drugs such as low solubility, adverse effects, and multi drug resistance. We have compiled the data of recent studies using the new hybrid anticancer drugs in cancer treatment. Thus, the design, synthesis and clinical trials of new hybrid compounds should be continued and supported in future. Results of recent studies have proved that they have a great potential to be used as novel anticancer drugs.
Keywords: Hybrid Compounds, Cancer, Anticancer Agents, Multitarget Compounds, Drug Design, Natural Products.
Current Topics in Medicinal Chemistry
Title:Hybrid Compounds as Multitarget Directed Anticancer Agents
Volume: 17 Issue: 8
Author(s): Ertan Kucuksayan and Tomris Ozben
Affiliation:
Keywords: Hybrid Compounds, Cancer, Anticancer Agents, Multitarget Compounds, Drug Design, Natural Products.
Abstract: Cancer is a multifactorial disease including interactions of complex genetic and environmental factors. Clinical efficacy of anticancer chemotherapies is hampered by various factors including multidrug resistance (MDR). There is a strong need to discover more potent novel cancer drugs to kill cancer cells selectively. The recent new strategy for cancer treatment involves the design and synthesis of hybrid compounds as multitargeted anticancer agents. In this review, we focus on studies using hybrid compounds which were designed and synthesized from two or more different bioactive moieties conjugating them into a single hybrid drug. Hybrid compounds having more than a single target have been considered as more efficient and potent anticancer agents, since it is almost impossible to destroy cancer cells with a single target. Hybrid compounds overcome many disadvantages of single cancer drugs such as low solubility, adverse effects, and multi drug resistance. We have compiled the data of recent studies using the new hybrid anticancer drugs in cancer treatment. Thus, the design, synthesis and clinical trials of new hybrid compounds should be continued and supported in future. Results of recent studies have proved that they have a great potential to be used as novel anticancer drugs.
Export Options
About this article
Cite this article as:
Kucuksayan Ertan and Ozben Tomris, Hybrid Compounds as Multitarget Directed Anticancer Agents, Current Topics in Medicinal Chemistry 2017; 17 (8) . https://dx.doi.org/10.2174/1568026616666160927155515
DOI https://dx.doi.org/10.2174/1568026616666160927155515 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Epigenetic Origin of Aneuploidy
Current Genomics Editorial (Thematic Issue: Novel Methods and Tools of the Computational Systems Biology in Bioinformatics and Biomedical Informatics)
Current Bioinformatics Thalidomide as an Immunotherapeutic Agent: The Effects on Neutrophil- Mediated Inflammation
Current Pharmaceutical Design The Expression of Dopamine Receptors Gene and their Potential Role in Targeting Breast Cancer Cells with Selective Agonist and Antagonist Drugs. Could it be the Novel Insight to Therapy?
Current Drug Discovery Technologies Adiponectin: A Key Player in Obesity Related Disorders
Current Pharmaceutical Design FOXP2 Promotes Tumor Proliferation and Metastasis by Targeting GRP78 in Triple-negative Breast Cancer
Current Cancer Drug Targets The Role of Snail in EMT and Tumorigenesis
Current Cancer Drug Targets Therapeutic Potential of Inhibiting Brutons Tyrosine Kinase, (BTK)
Current Pharmaceutical Design Phytoestrogen Genistein and Its Pharmacological Interactions with Synthetic Endocrine-Active Compounds
Current Pharmaceutical Design On the Power of Additional and Complex Chromosomal Aberrations in CML
Current Genomics Kinase Inhibitors Targeting Anti-angiogenesis as Anti-cancer Therapies
Current Angiogenesis (Discontinued) Molecular Interaction and Computational Analytical Studies of Pinocembrin for its Antiangiogenic Potential Targeting VEGFR-2: A Persuader of Metastasis
Medicinal Chemistry Novel Targeted Therapies to Overcome Trastuzumab Resistance in HER2- Overexpressing Metastatic Breast Cancer
Current Drug Targets Linking Fold, Function and Phylogeny: A Comparative Genomics View on Protein (Domain) Evolution
Current Genomics Vascular Homing Peptides with Cell-Penetrating Properties
Current Pharmaceutical Design The Roles of Vitamin D and Its Analogs in Inflammatory Diseases
Current Topics in Medicinal Chemistry Modulation and Absorption of Xenobiotics: The Synergistic Role of CYP450 and P-gp Activities in Cancer and Neurodegenerative Disorders
Current Drug Metabolism Natural Products Targeting Autophagy via the PI3K/Akt/mTOR Pathway as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Use of Gene Markers as a Novel Method to Predict Loss of Ovarian Function Due to Breast Cancer Treatment
Current Women`s Health Reviews LC/MS/MS Profiling of Tissue Oxysterols and its Application in Dextran Sodium Sulphate Induced Mouse Colitis Models
Current Topics in Medicinal Chemistry